206 related articles for article (PubMed ID: 37504367)
1. Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour-State of the Art and Perspectives.
Nappo G; Funel N; Laurenti V; Stenner E; Carrara S; Bozzarelli S; Spaggiari P; Zerbi A
Curr Oncol; 2023 Jul; 30(7):6996-7006. PubMed ID: 37504367
[TBL] [Abstract][Full Text] [Related]
2. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology.
Palmeri M; Funel N; Franco GD; Furbetta N; Gianardi D; Guadagni S; Bianchini M; Pollina LE; Ricci C; Chiaro MD; Candio GD; Morelli L
World J Gastroenterol; 2020 Nov; 26(43):6822-6836. PubMed ID: 33268964
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of ampulla of Vater cancer subtype classification based on immunohistochemical staining.
Kwon CH; Ahn JH; Seo HI; Kim DU; Han SY; Kim S; Lee NK; Hong SB; Park YM; Noh BG
World J Surg Oncol; 2024 Jan; 22(1):5. PubMed ID: 38167037
[TBL] [Abstract][Full Text] [Related]
4. [Combined application of immunohistochemical markers to identify pathologic subtypes of ampullary carcinoma and its clinical significance].
Liu FF; Shen DH; Wang HL; Ma YT; Yuan F; Liu J; Chen L; Song QJ; Zhang YY
Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):92-97. PubMed ID: 30695858
[No Abstract] [Full Text] [Related]
5. Immunohistochemical Classification of Ampullary Carcinomas: Critical Reappraisal Fails to Confirm Prognostic Relevance for Recently Proposed Panels, and Highlights MUC5AC as a Strong Prognosticator.
Xue Y; Reid MD; Balci S; Quigley B; Muraki T; Memis B; Xia J; Hacihasanoglu E; Bedolla G; Pehlivanoglu B; Kim GE; Tajiri T; Ohike N; Aneja R; Krasinskas AM; Adsay V
Am J Surg Pathol; 2017 Jul; 41(7):865-876. PubMed ID: 28505002
[TBL] [Abstract][Full Text] [Related]
6. The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater.
Ang DC; Shia J; Tang LH; Katabi N; Klimstra DS
Am J Surg Pathol; 2014 Oct; 38(10):1371-9. PubMed ID: 24832159
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2.
Chu PG; Schwarz RE; Lau SK; Yen Y; Weiss LM
Am J Surg Pathol; 2005 Mar; 29(3):359-67. PubMed ID: 15725805
[TBL] [Abstract][Full Text] [Related]
8. Differentiation and prognostic markers in ampullary cancer: Role of p53, MDM2, CDX2, mucins and cytokeratins.
Perysinakis I; Minaidou E; Mantas D; Sotiropoulos GC; Leontara V; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Pathol Res Pract; 2016 Nov; 212(11):1039-1047. PubMed ID: 27688085
[TBL] [Abstract][Full Text] [Related]
9. The use of histopathological subtyping in patients with ampullary cancer: a nationwide analysis.
de Bakker J; Sommeijer D; Besselink M; Kazemier G; van Grieken N
World J Surg Oncol; 2022 Dec; 20(1):406. PubMed ID: 36566267
[TBL] [Abstract][Full Text] [Related]
10. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin.
Bronsert P; Kohler I; Werner M; Makowiec F; Kuesters S; Hoeppner J; Hopt UT; Keck T; Bausch D; Wellner UF
BMC Cancer; 2013 Sep; 13():428. PubMed ID: 24053229
[TBL] [Abstract][Full Text] [Related]
11. Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival.
Williams JL; Chan CK; Toste PA; Elliott IA; Vasquez CR; Sunjaya DB; Swanson EA; Koo J; Hines OJ; Reber HA; Dawson DW; Donahue TR
JAMA Surg; 2017 Jan; 152(1):82-88. PubMed ID: 27732711
[TBL] [Abstract][Full Text] [Related]
12. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas.
Perysinakis I; Minaidou E; Leontara V; Mantas D; Sotiropoulos GC; Tsipras H; Zografos GN; Margaris I; Kouraklis G
Int J Surg Pathol; 2017 Feb; 25(1):31-40. PubMed ID: 27543509
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of ampullary carcinomas classifies ampullary carcinomas into biliary-like and intestinal-like subtypes that are prognostic of outcome.
Overman MJ; Zhang J; Kopetz S; Davies M; Jiang ZQ; Stemke-Hale K; Rümmele P; Pilarsky C; Grützmann R; Hamilton S; Hwang R; Abbruzzese JL; Varadhachary G; Broom B; Wang H
PLoS One; 2013; 8(6):e65144. PubMed ID: 23776447
[TBL] [Abstract][Full Text] [Related]
14. Non-ampullary-duodenal carcinomas: clinicopathologic analysis of 47 cases and comparison with ampullary and pancreatic adenocarcinomas.
Xue Y; Vanoli A; Balci S; Reid MM; Saka B; Bagci P; Memis B; Choi H; Ohike N; Tajiri T; Muraki T; Quigley B; El-Rayes BF; Shaib W; Kooby D; Sarmiento J; Maithel SK; Knight JH; Goodman M; Krasinskas AM; Adsay V
Mod Pathol; 2017 Feb; 30(2):255-266. PubMed ID: 27739441
[TBL] [Abstract][Full Text] [Related]
15. Intrapancreatic distal common bile duct carcinoma: Analysis, staging considerations, and comparison with pancreatic ductal and ampullary adenocarcinomas.
Gonzalez RS; Bagci P; Basturk O; Reid MD; Balci S; Knight JH; Kong SY; Memis B; Jang KT; Ohike N; Tajiri T; Bandyopadhyay S; Krasinskas AM; Kim GE; Cheng JD; Adsay NV
Mod Pathol; 2016 Nov; 29(11):1358-1369. PubMed ID: 27469329
[TBL] [Abstract][Full Text] [Related]
16. Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study.
Perkins G; Svrcek M; Bouchet-Doumenq C; Voron T; Colussi O; Debove C; Merabtene F; Dumont S; Sauvanet A; Hammel P; Cros J; André T; Bachet JB; Bardier A; Douard R; Meatchi T; Peschaud F; Emile JF; Cojean-Zelek I; Laurent-Puig P; Taieb J
Br J Cancer; 2019 Apr; 120(7):697-702. PubMed ID: 30837681
[TBL] [Abstract][Full Text] [Related]
17. Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma.
Cheng J; Mao Y; Hong W; Hu W; Shu P; Huang K; Yu J; Jiang M; Li L; Wang W; Ni D; Li S
J Transl Med; 2022 Jun; 20(1):272. PubMed ID: 35705951
[TBL] [Abstract][Full Text] [Related]
18. Performance and prognostic utility of the 92-gene assay in the molecular subclassification of ampullary adenocarcinoma.
Overman MJ; Soifer HS; Schueneman AJ; Ensor J; Adsay V; Saka B; Neishaboori N; Wolff RA; Wang H; Schnabel CA; Varadhachary G
BMC Cancer; 2016 Aug; 16(1):668. PubMed ID: 27549176
[TBL] [Abstract][Full Text] [Related]
19. Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas.
Ohike N; Coban I; Kim GE; Basturk O; Tajiri T; Krasinskas A; Bandyopadhyay S; Morohoshi T; Shimada Y; Kooby DA; Staley CA; Goodman M; Adsay NV
Am J Surg Pathol; 2010 Oct; 34(10):1417-24. PubMed ID: 20871215
[TBL] [Abstract][Full Text] [Related]
20. Identification of ampullary carcinoma mixed subtype using a panel of six antibodies and its clinical significance.
Liu F; Shen D; Ma Y; Song Q; Wang H
J Surg Oncol; 2019 Mar; 119(3):295-302. PubMed ID: 30548547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
